Investigational New Drugs

, Volume 22, Issue 3, pp 307–313 | Cite as

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

  • Paulo M. Hoff
  • Everardo D. Saad
  • Richard Pazdur
  • Robert Wolff
  • Yvonne Lassere
  • Karla R. Bogaard
  • James L. Abbruzzese


Background: Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined irinotecan and oxaliplatin given every three weeks. Methods: Cohorts of patients with MCC previously treated with 5-fluorouracil received escalating doses of irinotecan (150, 175, and 200 mg/m2) and a fixed dose of oxaliplatin (130 mg/m2), both given intravenously every 3 weeks. DLT was evaluated within the first course of treatment. Objective responses were evaluated every two courses and were confirmed at least four weeks later. Results: Fourteen patients were treated and evaluated for toxicity. The DLT was neutropenia, with or without fever, and delayed recovery of neutrophil counts was frequent (13 courses in six patients). Other toxic effects (peripheral neuropathy, nausea, vomiting, diarrhea, and fatigue) were mild to moderate. Among 13 patients evaluable for activity, four achieved partial responses and nine had stable disease. Conclusion: The combination of irinotecan and oxaliplatin is safe and apparently active in the treatment of MCC patients. The recommended dose for phase II studies is 175 mg/m2 irinotecan plus 130 mg/m2 oxaliplatin, given every 3 weeks. Neutropenia and delayed recovery of neutrophil counts are the predominant early toxicities with this schedule.

colorectal neoplasms drug therapy phase I irinotecan oxaliplatin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics. CA Cancer J Clin 53: 5–26, 2003PubMedGoogle Scholar
  2. 2.
    Ardalan B, Luis R, Jaime M, Franceschi D: Biomodulation of fluorouracil in colorectal cancer. Cancer Invest 16: 237–251, 1998PubMedGoogle Scholar
  3. 3.
    Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308, 1998Google Scholar
  4. 4.
    Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418, 1989PubMedGoogle Scholar
  5. 5.
    Poon MA, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967–1972, 1991Google Scholar
  6. 6.
    Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903, 1992Google Scholar
  7. 7.
    Pitot HC, Wender DB, O’Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910–2919, 1997PubMedGoogle Scholar
  8. 8.
    Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N’Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95–98, 1996Google Scholar
  9. 9.
    Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128–1135, 1996PubMedGoogle Scholar
  10. 10.
    Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9: 105–108, 1998PubMedGoogle Scholar
  11. 11.
    Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G, Rougier P: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16: 2739–2744, 1998PubMedGoogle Scholar
  12. 12.
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905–914, 2000CrossRefPubMedGoogle Scholar
  13. 13.
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041–1047, 2000CrossRefPubMedGoogle Scholar
  14. 14.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947, 2000PubMedGoogle Scholar
  15. 15.
    Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726, 1988PubMedGoogle Scholar
  16. 16.
    Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9: 1053–1071, 1998PubMedGoogle Scholar
  17. 17.
    Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5: 1189–1196, 1999PubMedGoogle Scholar
  18. 18.
    Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, Ouldkaci M, Besmaine A, Dupont-Andre G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17: 1751–1759, 1999PubMedGoogle Scholar
  19. 19.
    Kemeny N, Tong W, Gonen M, Stockman J, DiLauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol 13: 1490–1496, 2002PubMedGoogle Scholar
  20. 20.
    Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E: Severe CPT-11 toxicity in patients with Gilbert’s syndrome: Two case reports. Ann Oncol 8: 1049–1051, 1997PubMedGoogle Scholar
  21. 21.
    Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL, Cvitkovic E: Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 11: 1463–1470, 2000PubMedGoogle Scholar
  22. 22.
    Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP: N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. (Abstract) Proc Am Soc Clin Oncol 22: 252, 2003Google Scholar
  23. 23.
    Scheithauer W, Kornek GV, Raderer M, Valencak J, Weinlander G, Hejna M, Haider K, Kwasny W, Depisch D: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 17: 902–906, 1999PubMedGoogle Scholar
  24. 24.
    Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407–1412, 1995PubMedGoogle Scholar
  25. 25.
    Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223–3229, 1997PubMedGoogle Scholar
  26. 26.
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322–1327, 2000PubMedGoogle Scholar
  27. 27.
    Bismuth H, Adam R: Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 25(2 suppl 5): 40–46, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Paulo M. Hoff
    • 1
  • Everardo D. Saad
    • 2
  • Richard Pazdur
    • 3
  • Robert Wolff
    • 1
  • Yvonne Lassere
    • 1
  • Karla R. Bogaard
    • 1
  • James L. Abbruzzese
    • 1
  1. 1.Department of Gastrointestinal Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHouston
  2. 2.Albert Einstein HospitalSão PauloBrazil
  3. 3.U.S. Food and Drug AdministrationRockvilleUSA

Personalised recommendations